Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-07
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to
evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary
efficacy of ABO2011 monotherapy in patients with advanced solid tumors who have progressed or
metastasized after systemic standard of treatment.